Scholarlink

Background <p>The update of the World Health Organisation (WHO) classification of skin tumours has led to new aspects in the classification of melanocytic tumours.</p> Objectives <p>Presentation of the classification of melanocytic tumours in light of current clinical, histological and genetic data.</p> Materials and methods <p>Review of the classification of melanocytic neoplasms in the fifth edition of the WHO classification of skin tumours, taking into account current disease concepts.</p> Results <p>Malignant melanoma is characterised by stepwise tumour progression and is a&#xa0;heterogeneous disease. Benign and intermediate precursor lesions with characteristic driver mutations can be defined for the different melanoma subtypes. Melanocytomas represent a&#xa0;growing group of intermediate neoplasms which, from a&#xa0;genetic point of view, lie between nevi and melanomas and usually have a&#xa0;benign course.</p> Conclusion <p>With the update of the WHO classification, genetic parameters are becoming increasingly relevant and shape the terminology. New terms such as ‘melanocytoma’ require a&#xa0;medical understanding of current disease concepts and good physician–patient communication for appropriate reporting of findings and therapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

WHO-Klassifikation melanozytärer Tumoren

  • 期刊论文

  • 发表日期：

    2025年1月28日

查看全文
  • Maximilian Gassenmaier

摘要

Background

The update of the World Health Organisation (WHO) classification of skin tumours has led to new aspects in the classification of melanocytic tumours.

Objectives

Presentation of the classification of melanocytic tumours in light of current clinical, histological and genetic data.

Materials and methods

Review of the classification of melanocytic neoplasms in the fifth edition of the WHO classification of skin tumours, taking into account current disease concepts.

Results

Malignant melanoma is characterised by stepwise tumour progression and is a heterogeneous disease. Benign and intermediate precursor lesions with characteristic driver mutations can be defined for the different melanoma subtypes. Melanocytomas represent a growing group of intermediate neoplasms which, from a genetic point of view, lie between nevi and melanomas and usually have a benign course.

Conclusion

With the update of the WHO classification, genetic parameters are becoming increasingly relevant and shape the terminology. New terms such as ‘melanocytoma’ require a medical understanding of current disease concepts and good physician–patient communication for appropriate reporting of findings and therapy.